FLAMSA-MEL regimen

WikiDoc Resources for FLAMSA-MEL regimen
Articles
Most recent articles on FLAMSA-MEL regimen Most cited articles on FLAMSA-MEL regimen Review articles on FLAMSA-MEL regimen Articles on FLAMSA-MEL regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on FLAMSA-MEL regimen Images of FLAMSA-MEL regimen Photos of FLAMSA-MEL regimen Podcasts & MP3s on FLAMSA-MEL regimen Videos on FLAMSA-MEL regimen
Evidence Based Medicine
Cochrane Collaboration on FLAMSA-MEL regimen Bandolier on FLAMSA-MEL regimen TRIP on FLAMSA-MEL regimen
Clinical Trials
Ongoing Trials on FLAMSA-MEL regimen at Clinical Trials.gov Trial results on FLAMSA-MEL regimen Clinical Trials on FLAMSA-MEL regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on FLAMSA-MEL regimen NICE Guidance on FLAMSA-MEL regimen NHS PRODIGY Guidance FDA on FLAMSA-MEL regimen CDC on FLAMSA-MEL regimen
Books
Books on FLAMSA-MEL regimen
News
FLAMSA-MEL regimen in the news Be alerted to news on FLAMSA-MEL regimen News trends on FLAMSA-MEL regimen
Commentary
Blogs on FLAMSA-MEL regimen
Definitions
Definitions of FLAMSA-MEL regimen
Patient Resources / Community
Patient resources on FLAMSA-MEL regimen Discussion groups on FLAMSA-MEL regimen Patient Handouts on FLAMSA-MEL regimen Directions to Hospitals Treating FLAMSA-MEL regimen Risk calculators and risk factors for FLAMSA-MEL regimen
Healthcare Provider Resources
Symptoms of FLAMSA-MEL regimen Causes & Risk Factors for FLAMSA-MEL regimen Diagnostic studies for FLAMSA-MEL regimen Treatment of FLAMSA-MEL regimen
Continuing Medical Education (CME)
CME Programs on FLAMSA-MEL regimen
International
FLAMSA-MEL regimen en Espanol FLAMSA-MEL regimen en Francais
Business
FLAMSA-MEL regimen in the Marketplace Patents on FLAMSA-MEL regimen
Experimental / Informatics
List of terms related to FLAMSA-MEL regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:

Overview

FLAMSA-MEL regimen refers to a regimen consisting of fludarabine, amsacrine, cytarabine (Ara-C) and melphalan used to upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia.

Regimen

FLFludarabine

AMSAmsacrine

ACytarabine (Ara-C)

MELMelphalan

Indications

• Myelodysplastic syndrome or secondary Acute myeloid leukemia